title: MMP Inhibitors: Past, present and future.
abstract: Development of inhibitors of matrix metalloproteinases (MMPs) has been fraught with challenges. Early compounds largely failed due to poor selectivity and bioavailability. Dose-limiting side effects, off-target interactions, and improperly designed clinical trials significantly impeded clinical success. As information becomes available and technology evolves, tools to combat these obstacles have been developed. Improved methods for high throughput screening and drug design have led to identification of compounds exhibiting high potency, binding affinity, and favorable pharmacokinetic profiles. Current research into MMP inhibitors employs innovative approaches for drug delivery methods and allosteric inhibitors. Such innovation is key for development of clinically successful compounds.
authors.forename: Jillian M
authors.initials: JM
authors.lastname: Cathcart
authors.affiliation: Department of Medicine, Stony Brook University, Stony Brook, NY 11794, jian.cao@sunysb.edu.
authors.forename: Jian
authors.initials: J
authors.lastname: Cao
mesh_terms: D001665:Binding Sites; D019295:Computational Biology; D016503:Drug Delivery Systems / Q000639:trends; D055808:Drug Discovery; D061965:Matrix Metalloproteinase Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D057786:Peptidomimetics / Q000737:chemistry* / Q000627:therapeutic use; D013752:Tetracycline / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; D057786:Peptidomimetics; D013752:Tetracycline